Hyperion’s Orphan Drug Ravicti Clears FDA; Postmarket Studies Required
This article was originally published in The Pink Sheet Daily
Hyperion will launch the drug for treatment of urea cycle disorders in April, and the firm will need to plan a 10-year registry for patients.
You may also be interested in...
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.
Operation Warp Speed confirmed the necessity of having a facility on hand to develop and manufacture a vaccine for the next crisis, the outgoing advisor says.
Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.